0001209191-23-002542.txt : 20230109 0001209191-23-002542.hdr.sgml : 20230109 20230109160438 ACCESSION NUMBER: 0001209191-23-002542 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220729 FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Race Geoffrey CENTRAL INDEX KEY: 0001831607 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37718 FILM NUMBER: 23518113 MAIL ADDRESS: STREET 1: C/O EDDEVA B920 STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: F-star Therapeutics, Inc. CENTRAL INDEX KEY: 0001566373 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522386345 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 44 1223 497400 MAIL ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-29 0 0001566373 F-star Therapeutics, Inc. FSTX 0001831607 Race Geoffrey C/O F-STAR THERAPEUTICS, INC. EDDEVA B920, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 1 0 0 0 Common Stock 2022-07-29 4 M 0 3937 0.11 A 3937 D Stock Option (right to buy) 0.11 2022-07-29 4 M 0 3937 0.00 D 2029-12-18 Common Stock 3937 3937 D This Report is reporting the exempt exercise of employee stock options for cash payment thereof and receipt of the resulting shares. No shares were sold incidental to the exercise of these stock options. This exercise price was originally reported incorrectly as $0.08 per share due to a conversion rate error from Pound Sterling into U.S. Dollars. Using the August 2022 approximate exchange rate of 1.2211, the exercise price in U.S. Dollars would be approximately $0.11 per share. Shall vest in 12 equal monthly installments so long as he remains a director of the company. /s/ Darlene Deptula-Hicks, Attorney-in-fact 2023-01-09